B cells in autoimmunity

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  Dörner, Thomas ^a   Jacobi, Annett M ^a   Lipsky, Peter E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD16 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FC GAMMA RECEPTOR 5; FC RECEPTOR; FC RECEPTOR IIB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL MATURATION; CYTOKINE PRODUCTION; DNA POLYMORPHISM; EFFECTOR CELL; GENE AMPLIFICATION; HUMAN; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; MEMORY CELL; PLASMA CELL; PROMOTER REGION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CYTOLOGY; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION;

EID: 75649118248     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2780     Document Type: Review

References (81)

1. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
2. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398. 1895038, 15701725.
3. Milner EC, Anolik J, Cappione A, Sanz I. Human innate B cells: a link between host defense and autoimmunity?. Springer Semin Immunopathol 2005, 26:433-452. 1431976, 15633016.
4. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dörner T. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171.
5. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
6. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5(+) pre-naive B cell population. J Immunol 2009, 182:4116-4126.
7. Won WJ, Laessing U, Bachmann M, Kearney J. Expression of CD36 by mouse marginal zone B cell. FASEB J 2005, 19:A358.
8. Tarlinton D. B-cell memory: are subsets necessary?. Nat Rev Immunol 2006, 6:785-790.
9. Peter HH, Warnatz K. Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity. Expert Opin Biol Ther 2005, 5:S61-S71.
10. Warnatz K, Bossaller L, Salzer U, Skrabl-Baumgartner A, Schwinger W, Burg M, van Dongen JJ, Orlowska-Volk M, Knoth R, Durandy A, Draeger R, Schlesier M, Peter HH, Grimbacher B. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 2006, 107:3045-3052.
11. Isenberg D, Rahman A. Systemic lupus erythematosus - 2005 annus mirabilis?. Nat Clin Pract Rheumatol 2006, 2:145-152.
12. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. In undifferentiated arthritis autoantibodies to cyclic citrullinated peptides (CCP) predict progression to rheumatoid arthritis: a prospective cohort study [abstract]. Arthritis Rheum 2003, 48:S108.
13. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis - A prospective cohort study. Arthritis Rheum 2004, 50:709-715.
14. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005, 201:703-711. 2212839, 15738055.
15. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H, Nussenzweig MC. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006, 203:2255-2261. 2118096, 16966430.
16. Cappione A 3, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005, 115:3205-3216. 1242189, 16211091.
17. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dörner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
18. Jahn S, Neimann B, Winkler T, Kalden JR, Vonbaehr R. Expansion of A B-lymphocyte clone producing Igm autoantibodies encoded by a somatically mutated V(H)J gene in the spleen of an autoimmune patient. Rheumatol Int 1994, 13:187-196.
19. Zhang J, Jacobi AM, Wang T, Diamond B. Pathogenic autoantibodies in systemic lupus erythematosus are derived from both self-reactive and non-self-reactive B cells. Mol Med 2008, 14:675-681. 2493535,2493535, 18677426.
20. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
21. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dörner T. Correlation between circulating CD27(high) plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342.
22. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch AH, Burmester GR, Hiepe F, Dörner T. HLA-DRhigh/CD27highplasmablasts indicate active disease in patients with SLE. Ann Rheum Dis 2009,
23. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-1584. 2211779, 15173206.
24. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750.
25. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dörner T. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009, 113:2461-2469.
26. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, Berek C, Hiepe F, Manz R, Radbruch A, Dörner T. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105:1614-1621.
27. Dörner T, Lipsky PE. Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. Clin Exp Med 2005, 4:159-169.
28. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG(+) memory B cells. Immunity 2007, 26:205-213. 1839941, 17306569.
29. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med 2000, 191:1253-1257. 2193170, 10748243.
30. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dörner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus - Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773.
31. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.
32. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JL. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. 1951. J Am Soc Nephrol 2000, 11:183-188.
33. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007, 96:179-204.
34. Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc gamma RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
35. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999, 72:149-177.
36. Dörner T, Lipsky PE. Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 2006, 305:213-240.
37. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996, 379:346-349.
38. Crowley JE, Stadanlick JE, Cambier JC, Cancro MP. Fc gamma RIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood 2009, 113:1464-1473.
39. Blank MC, Stefanescu RN, Masuda E, Marti F, King PD, Redecha PB, Wurzburger RJ, Peterson MG, Tanaka S, Pricop L. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005, 117:220-227.
40. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, Lehner PJ, Ouwehand WH, Allen JM, Watkins NA, Smith KG. Loss of function of a lupus-associated Fc gamma RIIb polymorphism through exclusion from lipid rafts. Nat Med 2005, 11:1056-1058.
41. Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, Lehner PJ, Ouwehand WH, Allen JM, Watkins NA, Smith KG. A polymorphism of the inhibitory receptor, Fc gamma RIIb, prevents its access to lipid rafts and alters macrophage responses to immune complexes and opsonized bacteria. Clin Immunol 2005, 115:S214.
42. Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB, Staudt LM, Young JW, Nussenzweig MC. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000, 1:207-213.
43. Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004, 172:803-811.
44. O'Neill SK, Cao YX, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 2007, 179:5109-5116.
45. Chan OTM, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1647. 2193634, 10330443.
46. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dörner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67:450-457.
47. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH, Warnatz K. A new CD21(low) B cell population in the peripheral blood of patients with SLE. Clin Immunol 2004, 113:161-171.
48. Briere F, Servetdelprat C, Bridon J, Saintremy JM, Banchereau J. Human interleukin-10 induces naive surface-immunoglobulin D+ (Sigd(+)) B-cells to secrete Igg1 and Igg3. J Exp Med 1994, 179:757-762. 2191366, 8294883.
49. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
50. Pène J, Gauchat JF, Lécart S, Drouet E, Guglielmi P, Boulay V, Delwail A, Foster D, Lecron JC, Yssel H. Cutting edge: IL-21 is a switch factor for the production of IgG(1) and IgG(3) by human B cells. J Immunol 2004, 172:5154-5157.
51. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, Leonard WJ, Lipsky PE. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005, 175:7867-7879.
52. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:F59-F63. 2193578, 11748288.
53. Lindh E, Lind SM, Lindmark E, Hässler S, Perheentupa J, Peltonen L, Winqvist O, Karlsson MC. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci USA 2008, 105:18466-18471. 2587634, 19011083.
54. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68. 150825, 11781351.
55. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005, 174:864-870.
56. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8:391-397.
57. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520. 259134, 14617752.
58. Hutloff A, Büchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dörner T, Kroczek RA. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220.
59. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, . BG9588 Lupus Nephritis Trial Group A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727. BG9588 Lupus Nephritis Trial Group.
60. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008, 67:83-86. 19022821.
61. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, Yu D, Domaschenz H, Whittle B, Lambe T, Roberts IS, Copley RR, Bell JI, Cornall RJ, Goodnow CC. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
62. Ettinger R, Kuchen S, Lipsky PE. The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 2008, 223:60-86.
63. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of a cells within the target tissue of an autoimmune disease - The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998, 102:938-946. 508959, 9727062.
64. Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005, 37:820-828.
65. Salzer U, Grimbacher B. TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol 2005, 5:496-503.
66. Salzer U, Chapel HM, Webster AD, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, Peter HH, Rockstroh JK, Schneider P, Schäffer AA, Hammarström L, Grimbacher B. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005, 37:820-828.
67. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005, 37:829-834.
68. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H, Geha RS. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005, 201:35-39. 2212754, 15630136.
69. Evans CH, Ghivizzani SC, Oligino TJ, Robbins PD. Gene therapy for autoimmune disorders. J Clin Immunol 2000, 20:334-346.
70. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331. 2212997, 16027240.
71. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202:1171-1177. 2213226, 16260486.
72. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
73. Burmester GR, Horneff G, Emmrich F, Kalden JR. Treatment of rheumatoid-arthritis with an anti-Cd4 monoclonal-antibody. Arthritis Rheum 1991, 34:129-140. 1994909, 1994909.
74. Hiepe F, Volk HD, Apostoloff E, Vonbaehr R, Emmrich F. Treatment of severe systemic lupus-erythematosus with anti-Cd4 monoclonal-antibody. Lancet 1991, 338:1529-1530.
75. Iwai H, Abe M, Hirose S, Tsushima F, Tezuka K, Akiba H, Yagita H, Okumura K, Kohsaka H, Miyasaka N, Azuma M. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003, 171:2848-2854.
76. Dörner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008, 20:263-268.
77. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
78. Thurlings RM, Vos K, Wijbrandts CA, Gerlag DM, Tak PP. Dynamics of the synovial B cell response to rituximab therapy in rheumatoid arthritis: evaluation of serial synovial biopsies during the first four months of treatment [abstract]. Ann Rheum Dis 2007, 66:123.
79. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
80. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Gordon C, Hsieh H, Brunetta P. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER [abstract]. Arthritis Rheum 2008, 58:4029-4030.
81. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R74. 1526638, 16630358.